Trials / Completed
CompletedNCT04693351
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 589 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Troriluzole | Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten. |
| DRUG | Placebo | Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten. |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2025-04-29
- Completion
- 2025-04-29
- First posted
- 2021-01-05
- Last updated
- 2025-08-19
Locations
89 sites across 7 countries: United States, Canada, China, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04693351. Inclusion in this directory is not an endorsement.